Inhibrx Biosciences, Inc. (INBX)

In the past six months, Inhibrx Biosciences' stock has experienced significant events. On October 23, 2025, positive topline results from the ChonDRAgon study of ozekibart led to a stock price increase of over 102%. In November 2025, the company announced participation in scientific conferences and reported its Third Quarter 2025 Financial Results. In December 2025, Inhibrx Biosciences provided progress updates on its INBRX-106 program and the expansion cohorts of the ozekibart program. In March 2026, Inhibrx announced participation in an upcoming scientific conference and reported its Fourth Quarter and Fiscal Year 2025 Financial Results, detailing a net loss of $140.1 million for FY25. On April 7, 2026, Stifel initiated coverage with a "buy" rating and a price target of $150.00. On April 11, 2026, MarketBeat reported a consensus rating of "Hold" from five brokerages. The stock has seen significant appreciation, with a 431% increase over the past year as of April 7, 2026.

As a clinical-stage biopharmaceutical company, Inhibrx Biosciences, Inc. does not have commercialized products or services that would typically exhibit demand seasonality. Its financial performance is driven by clinical trial results, regulatory milestones, and investor sentiment surrounding its pipeline assets.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapeutic candidates for life-threatening conditions, primarily in oncology and rare diseases. The company was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc., following a corporate restructuring. The company utilizes protein engineering methods to develop therapeutic candidates, including Ozekibart (INBRX-109) for solid tumors and INBRX-106 for metastatic solid tumors.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. Its primary operations are focused on research and development.

In the past year, Inhibrx Biosciences' reputation has been tied to its clinical development progress and stock performance. The successful development of INBRX-101 and its acquisition by Sanofi delivered returns to shareholders. Positive topline results for ozekibart in chondrosarcoma in October 2025 boosted the stock price. Analyst ratings are currently mixed, with a consensus "Hold" rating.

Inhibrx Biosciences, Inc. has a mixed ownership structure, with institutional investors holding a significant portion. Approximately 55.16% to 64.25% of the company's stock is owned by institutional investors, 9.74% by insiders, and the remainder by public companies and individual investors. Major institutional owners include Perceptive Advisors Llc, Viking Global Investors Lp, Morgan Stanley, and Sanofi, among others.